Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
Mari Iida(Institute for Medical Research), Deric L. Wheeler(Institute for Medical Research)
Cited by 64
Related Papers
Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
|PLoS ONE|2013|27
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer
|BMC Cancer|2022|16
AXL Regulates Neuregulin1 Expression Leading to Cetuximab Resistance in Head and Neck Cancer
|Research Square|2021|1